Search Results - "ZORN, Kristin K"

Gene Expression Profiles of Serous, Endometrioid, and Clear Cell Subtypes of Ovarian and Endometrial Cancer by ZORN, Kristin K, BONOME, Tomas, GANGI, Lisa, CHANDRAMOULI, Gadisetti V. R, AWTREY, Christopher S, GARDNER, Ginger J, BARRETT, J. Carl, BOYD, Jeff, BITTER, Michael J

“…Purpose: The presence of similar histologic subtypes of epithelial ovarian and endometrial cancers has long been noted, although the relevance of this finding…”
Get full text

Statewide trends and factors associated with genetic testing for hereditary cancer risk in Arkansas 2013-2018 by Acharya, Mahip, Zorn, Kristin K, Simonson, Melinda E, Bimali, Milan, Moore, Gary W, Peng, Cheng, Martin, Bradley C

“…Early identification of hereditary cancer risk would save lives, but genetic testing (GT) has been inadequate. We assessed i) trends for hereditary breast and…”
Get full text

Challenges in recruiting African-American women for a breast cancer genetics study by Compadre, Amanda J, Simonson, Melinda E, Gray, Katy, Runnells, Gail, Kadlubar, Susan, Zorn, Kristin K

“…African-American women, especially in the southern United States, are underrepresented in cancer genetics research. A study was designed to address this issue…”
Get full text

High-Dose-Rate Rotte “Y” Applicator Brachytherapy for Definitive Treatment of Medically Inoperable Endometrial Cancer: 10-Year Results by Coon, Devin, B.A, Beriwal, Sushil, M.D, Heron, Dwight E., M.D, Kelley, Joseph L., M.D, Edwards, Robert P., M.D, Sukumvanich, Paniti, M.D, Zorn, Kristin K., M.D, Krivak, Thomas C., M.D

“…Purpose To assess the intermediate clinical outcomes of medically inoperable patients with endometrial cancer treated with definitive Rotte “Y” applicator…”
Get full text

Can Automated Alerts in the Electronic Health Record Encourage Referrals for Genetic Counseling and Testing Among Patients at High Risk for Hereditary Cancer Syndromes? by Zorn, Kristin K, Simonson, Melinda E, Faulkner, Jennifer L, Carr, Cyndee L, Acuna, Joshua, Hall, Tiffany L, Jenkins, John F, Drummond, Karen L, Curran, Geoffrey M

“…Up to 10% of cancers may be associated with an inherited mutation that increases cancer risk. National guidelines emphasize referral for genetic counseling and…”
Get more information

Gene Expression Profiles Associated with Response to Chemotherapy in Epithelial Ovarian Cancers by JAZAERI, Amir A, AWTREY, Christopher S, BARRETT, J. Carl, BOYD, Jeff, CHANDRAMOULI, Gadisetti V. R, CHUANG, Yao Eric, KHAN, Javed, SOTIRIOU, Christos, APRELIKOVA, Olga, YEE, Cindy J, ZORN, Kristin K, BIRRER, Michael J

“…Purpose: The goal of this study was to determine whether distinct gene expression profiles are associated with intrinsic and/or acquired chemoresistance in…”
Get full text

Surgery versus radiation therapy for stage IB2 cervical carcinoma: a population-based analysis by Rungruang, Bunja, Courtney-Brooks, Madeleine, Beriwal, Sushil, Zorn, Kristin K, Richard, Scott D, Olawaiye, Alexander B, Krivak, Thomas C, Sukumvanich, Paniti

“…The objective of the study was to examine outcomes in stage IB2 cervical cancer patients undergoing primary surgery versus radiation. Stage IB2 cervical cancer…”
Get more information

Choice of Normal Ovarian Control Influences Determination of Differentially Expressed Genes in Ovarian Cancer Expression Profiling Studies by ZORN, Kristin K, JAZAERI, Amir A, AWTREY, Christopher S, GARDNER, Ginger J, MOK, Samuel C, BOYD, Jeff, BIRRER, Michael J

“…Purpose: As with many cancers thought to be of epithelial origin, expression profiling studies of ovarian cancer have relied on a variety of sources of normal…”
Get full text

Phase II study of everolimus and bevacizumab in recurrent ovarian, peritoneal, and fallopian tube cancer by Taylor, Sarah E., Chu, Tianjiao, Elvin, Julia A., Edwards, Robert P., Zorn, Kristin K.

“…Recurrent ovarian, fallopian tube, and peritoneal cancers have limited potential for cure with traditional therapies. Preliminary results from a phase I study…”
Get full text

Germline and Somatic Testing in Ovarian Cancer: Shifting Sands of Recommendations by Moore, Kathleen N., Zorn, Kristin K.

Get full text

Germline pathogenic variants identified in women with ovarian tumors by Carter, Natalie J., Marshall, Megan L., Susswein, Lisa R., Zorn, Kristin K., Hiraki, Susan, Arvai, Kevin J., Torene, Rebecca I., McGill, Anna K., Yackowski, Lauren, Murphy, Patricia D., Xu, Zhixiong, Solomon, Benjamin D., Klein, Rachel T., Hruska, Kathleen S.

“…The recognition of genes implicated in ovarian cancer risk beyond BRCA1, BRCA2, and the Lynch syndrome genes has increased the variety of testing options…”
Get full text

BRCA1/2 mutations and expression: Response to platinum chemotherapy in patients with advanced stage epithelial ovarian cancer by Dann, Rebecca Byler, DeLoia, Julie A, Timms, Kirsten M, Zorn, Kristin K, Potter, Jennifer, Flake, Darl D, Lanchbury, Jerry S, Krivak, Thomas C

“…Abstract Objective Our objective was to determine the rate of BRCA1/2 deficiency in platinum-sensitive and platinum-resistant tumors from a cohort of unselect…”
Get full text

Use of Metformin in Obese Women With Type I Endometrial Cancer Is Associated With a Reduced Incidence of Cancer Recurrence by Hall, Christopher, Stone, Rebecca L, Gehlot, Ashita, Zorn, Kristin K, Burnett, Alexander F

“…Recent evidence suggests that hyperinsulinemia associated with obesity may be a significant risk factor for the development of endometrial cancer. Metformin is…”
Get more information

What’s in Between the Lines: Assessing the Readability, Understandability, and Actionability in Breast Cancer Survivorship Print Materials by Parker, Pearman D., Prabhu, Arpan V., Su, L. Joseph, Zorn, Kristin K., Greene, Carolyn J., Hadden, Kristie B., McSweeney, Jean C.

“…Educational print materials for young women breast cancer survivors (YBCS) are supplemental tools used in patient teaching. However, the readability of the…”
Get full text

Recurrent gynandroblastoma of the ovary with germline DICER1 mutation: A case report and review of the literature by Mercier, Ann Marie, Zorn, Kristin K., Quick, Charles M., Huffman, Laura B.

“…•Sertoli-Leydig cell tumor and gynandroblastoma are rare ovarian sex cord-stromal tumors that warrant germline DICER1 testing.•DICER1 mutations are associated…”
Get full text

Phase I study of intravenous oxaliplatin and intraperitoneal docetaxel in recurrent ovarian cancer by Taylor, Sarah E, Petschauer, Jennifer S, Donovan, Heidi, Schorzman, Allison, Razo, Juan, Zamboni, William C, Edwards, Robert P, Zorn, Kristin K

“…Intraperitoneal (IP) chemotherapy improves survival in ovarian cancer but its use has been limited by toxicity with cisplatin-based regimens. The primary…”
Get more information

Proteomic Analysis of Matched Formalin-Fixed, Paraffin-Embedded Specimens in Patients with Advanced Serous Ovarian Carcinoma by Smith, Ashlee L, Sun, Mai, Bhargava, Rohit, Stewart, Nicolas A, Flint, Melanie S, Bigbee, William L, Krivak, Thomas C, Strange, Mary A, Cooper, Kristine L, Zorn, Kristin K

“…The biology of high grade serous ovarian carcinoma (HGSOC) is poorly understood. Little has been reported on intratumoral homogeneity or heterogeneity of…”
Get full text

PARP inhibition in epithelial ovarian cancer: high hopes undergo a reality check by Zorn, Kristin K

“…The treatment strategy of poly(ADP-ribose) polymerase (PARP) inhibition capitalizes on the inherent defect in homologous recombination that occurs in…”
Get more information

Preoperative high dose rate brachytherapy for clinical stage II endometrial carcinoma by Shukla, Gaurav, Beriwal, Sushil, Krivak, Thomas C, Kelley, Joseph L, Sukumvanich, Paniti, Edwards, Robert P, Richard, Scott, Olawaiye, Alexander, Zorn, Kristin K

“…We sought to evaluate pathological response, tolerance, and outcome after preoperative (neoadjuvant) high dose rate brachytherapy in a small series of patients…”
Get full text

Perspectives on Self-Advocacy: Comparing Perceived Uses, Benefits, and Drawbacks Among Survivors and Providers by Hagan, Teresa, Rosenzweig, Margaret, Zorn, Kristin, van Londen, Josie, Donovan, Heidi

“…To describe and compare survivors' and providers' views of the uses of and perceived benefits and drawbacks of survivor self-advocacy. A cross-sectional,…”
Get full text